RARE DISEASE
Hypochondroplasia
Hypochondroplasia
Hypochondroplasia
Drug discovery
4
drugs
With orphan designations
Overview
Hypochondroplasia is a mild skeletal dysplasia caused by FGFR3 mutations, leading to disproportionate short stature, limb shortening, and subtle dysmorphic features. Diagnosis combines clinical assessment, radiography (narrowed lumbar spine, short femoral necks), and genetic testing. Complications include spinal stenosis, leg bowing, and mild neurocognitive issues in ~10% [1][6][14]. Management focuses on monitoring growth, orthopedic interventions, and emerging therapies like vosoritide [3][8][12]. Life expectancy is normal.
Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases
Research Papers
109 drug discovery papers about Hypochondroplasia, with 3 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
109 drug discovery papers about Hypochondroplasia, with 3 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-28 | HK1-LDHA axis feedback regulation promotes histone lactylation of Wnt5a and mediates prenatal acetaminophen-induced susceptibility to osteoarthritis in male offspring.
Acetaminophen is widely used during pregnancy but may cause developmental abnormalities in multiple systems in offspring. However, the effects of prenatal acetaminophen exposure (PAcE) on chondrodevelopment and long-term outcomes remain unclear. We administered 100 mg/kg per day of acetaminophen to rats on gestational days (GDs) 10-12 and treated fetal chondrocytes in vitro. In male PAcE offspring, cartilage matrix synthesis decreased and degradation increased at GD20 and postnatal week 12, with osteoarthritis (OA) susceptibility after running. Females exhibited only reduced matrix content at GD20. Mechanistically, acetaminophen inhibited the expression of hexokinase 1 (HK1) in chondrocytes under both normoxic and hypoxic conditions in vitro. However, HK1 inhibition induced feedback enhancement of the glycolytic only under hypoxic conditions, which increased lactic acid production and H3K18la lactylation levels in the Wnt5a promoter region, disrupting cartilage homeostasis. These effects were reversed by Wnt5a knockdown, HK1 overexpression, or LDHA knockdown. Finally, intra-articular adeno-associated virus-shWnt5a injection improved OA pathology in male PAcE offspring. In summary, PAcE upregulated H3K18la levels with Wnt5a through HK1-LDHA-mediated glycolytic feedback regulation, causing chondrodysplasia and increased OA susceptibility in male offspring, with sex differences. Our findings provide crucial insight into the hypoxia-dependent chondrotoxicity of PAcE, providing a reference for future research on fetal-derived OA. High H3K18la in the Wnt5a promoter region mediates PAcE-induced hypochondroplasia and susceptibility to adult OA in male offspring rats.
2026-06-03 | Navepegritide: First Approval.
Navepegritide (YUVIWEL®) is a prodrug of C-type natriuretic peptide (CNP) developed by Ascendis Pharma for the treatment of achondroplasia and is being investigated for hypochondroplasia. Navepegritide is administered once weekly and designed to provide sustained release and continuous exposure of active CNP, which is needed to counteract the overactive fibroblast growth factor receptor 3 signaling in achondroplasia, resulting in improved growth velocity. Navepegritide recently received accelerated approval in the USA for increasing linear growth in paediatric patients aged ≥ 2 years with achondroplasia with open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia.
2026-05-25 | Navepegritide: First Approval
DeclarationsAuthorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Abstract
Navepegritide (YUVIWEL®) is a prodrug of C-type natriuretic peptide (CNP) developed by Ascendis Pharma for the treatment of achondroplasia and is being investigated for hypochondroplasia. Navepegritide is administered once weekly and designed to provide sustained release and continuous exposure of active CNP, which is needed to counteract the overactive fibroblast growth factor receptor 3 signaling in achondroplasia, resulting in improved growth velocity. Navepegritide recently received accelerated approval in the USA for increasing linear growth in paediatric patients aged ≥ 2 years with achondroplasia with open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia.
© Springer Nature Switzerland AG 2026
2026-05-05 | Rare Short Stature Disorders in Childhood: Future Implications for Treatment and Gene Therapy Options
Rare childhood short stature disorders such as Achondroplasia, Hypochondroplasia, ACAN syndrome, and Noonan Syndrome are primarily caused by specific genetic mutations that disrupt normal bone growth and development. Advances in molecular diagnostics have improved early detection, while emerging gene therapy approaches—including CRISPR-Cas9—offer promising future strategies to target the underlying genetic defects. The review aims to focus on rare genetically determined dwarfism syndromes, including conditions such as achondroplasia, hypochondroplasia, ACAN syndrome, and Noonan syndrome, with a focus on their underlying genetic causes, clinical features, and diagnostic approaches. The present review was conducted using secondary sources derived from existing academic literature, including peer-reviewed journal articles, books, and conference proceedings. Achondroplasia, the most common form of dwarfism, and hypochondroplasia are primarily caused by activating mutations in the FGFR3 gene, leading to impaired endochondral ossification. In contrast, ACAN mutations affect cartilage structure and growth plate function, while Noonan syndrome involves mutations in genes of the RAS/MAPK signaling pathway, such as PTPN11. Gene therapy, including genome editing technologies such as CRISPR-Cas9, offer a prospective avenue for causal treatment by targeting the underlying genetic defects. Early detection through advanced genetic screening, potentially even prenatally, may further enhance therapeutic outcomes. This review highlights the growing potential of gene-based interventions while emphasizing the need for continued research to translate these approaches into safe and effective clinical applications.
2026-01-01 | P237: Incidence of neurocognitive conditions in hypochondroplasia
Hypochondroplasia is one of several well-described skeletal dysplasias that occur along the FGFR3-spectrum. While individuals with hypochondroplasia generally present more mildly from a skeletal perspective than achondroplasia, an increased incidence of attention/hyperactivity concerns, learning, and intellectual disability as well as seizures, has been reported in this population. For counseling and screening purposes there is limited information on both risk of neurocognitive diagnoses and role of MRI as a predictor of neurocognitive outcomes.
2026-07-28 | HK1-LDHA axis feedback regulation promotes histone lactylation of Wnt5a and mediates prenatal acetaminophen-induced susceptibility to osteoarthritis in male offspring.
Acetaminophen is widely used during pregnancy but may cause developmental abnormalities in multiple systems in offspring. However, the effects of prenatal acetaminophen exposure (PAcE) on chondrodevelopment and long-term outcomes remain unclear. We administered 100 mg/kg per day of acetaminophen to rats on gestational days (GDs) 10-12 and treated fetal chondrocytes in vitro. In male PAcE offspring, cartilage matrix synthesis decreased and degradation increased at GD20 and postnatal week 12, with osteoarthritis (OA) susceptibility after running. Females exhibited only reduced matrix content at GD20. Mechanistically, acetaminophen inhibited the expression of hexokinase 1 (HK1) in chondrocytes under both normoxic and hypoxic conditions in vitro. However, HK1 inhibition induced feedback enhancement of the glycolytic only under hypoxic conditions, which increased lactic acid production and H3K18la lactylation levels in the Wnt5a promoter region, disrupting cartilage homeostasis. These effects were reversed by Wnt5a knockdown, HK1 overexpression, or LDHA knockdown. Finally, intra-articular adeno-associated virus-shWnt5a injection improved OA pathology in male PAcE offspring. In summary, PAcE upregulated H3K18la levels with Wnt5a through HK1-LDHA-mediated glycolytic feedback regulation, causing chondrodysplasia and increased OA susceptibility in male offspring, with sex differences. Our findings provide crucial insight into the hypoxia-dependent chondrotoxicity of PAcE, providing a reference for future research on fetal-derived OA. High H3K18la in the Wnt5a promoter region mediates PAcE-induced hypochondroplasia and susceptibility to adult OA in male offspring rats.
2026-06-03 | Navepegritide: First Approval.
Navepegritide (YUVIWEL®) is a prodrug of C-type natriuretic peptide (CNP) developed by Ascendis Pharma for the treatment of achondroplasia and is being investigated for hypochondroplasia. Navepegritide is administered once weekly and designed to provide sustained release and continuous exposure of active CNP, which is needed to counteract the overactive fibroblast growth factor receptor 3 signaling in achondroplasia, resulting in improved growth velocity. Navepegritide recently received accelerated approval in the USA for increasing linear growth in paediatric patients aged ≥ 2 years with achondroplasia with open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia.
2026-05-25 | Navepegritide: First Approval
DeclarationsAuthorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Abstract
Navepegritide (YUVIWEL®) is a prodrug of C-type natriuretic peptide (CNP) developed by Ascendis Pharma for the treatment of achondroplasia and is being investigated for hypochondroplasia. Navepegritide is administered once weekly and designed to provide sustained release and continuous exposure of active CNP, which is needed to counteract the overactive fibroblast growth factor receptor 3 signaling in achondroplasia, resulting in improved growth velocity. Navepegritide recently received accelerated approval in the USA for increasing linear growth in paediatric patients aged ≥ 2 years with achondroplasia with open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia.
© Springer Nature Switzerland AG 2026
2026-05-05 | Rare Short Stature Disorders in Childhood: Future Implications for Treatment and Gene Therapy Options
Rare childhood short stature disorders such as Achondroplasia, Hypochondroplasia, ACAN syndrome, and Noonan Syndrome are primarily caused by specific genetic mutations that disrupt normal bone growth and development. Advances in molecular diagnostics have improved early detection, while emerging gene therapy approaches—including CRISPR-Cas9—offer promising future strategies to target the underlying genetic defects. The review aims to focus on rare genetically determined dwarfism syndromes, including conditions such as achondroplasia, hypochondroplasia, ACAN syndrome, and Noonan syndrome, with a focus on their underlying genetic causes, clinical features, and diagnostic approaches. The present review was conducted using secondary sources derived from existing academic literature, including peer-reviewed journal articles, books, and conference proceedings. Achondroplasia, the most common form of dwarfism, and hypochondroplasia are primarily caused by activating mutations in the FGFR3 gene, leading to impaired endochondral ossification. In contrast, ACAN mutations affect cartilage structure and growth plate function, while Noonan syndrome involves mutations in genes of the RAS/MAPK signaling pathway, such as PTPN11. Gene therapy, including genome editing technologies such as CRISPR-Cas9, offer a prospective avenue for causal treatment by targeting the underlying genetic defects. Early detection through advanced genetic screening, potentially even prenatally, may further enhance therapeutic outcomes. This review highlights the growing potential of gene-based interventions while emphasizing the need for continued research to translate these approaches into safe and effective clinical applications.
2026-01-01 | P237: Incidence of neurocognitive conditions in hypochondroplasia
Hypochondroplasia is one of several well-described skeletal dysplasias that occur along the FGFR3-spectrum. While individuals with hypochondroplasia generally present more mildly from a skeletal perspective than achondroplasia, an increased incidence of attention/hyperactivity concerns, learning, and intellectual disability as well as seizures, has been reported in this population. For counseling and screening purposes there is limited information on both risk of neurocognitive diagnoses and role of MRI as a predictor of neurocognitive outcomes.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
4 orphan drug designations for Hypochondroplasia.
4 orphan drug designations for Hypochondroplasia.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Infigratinib | small molecules | EMA | 2025-11-21 | — | BridgeBio Europe B.V. |
infigratinib | small molecules | FDA | 2025-06-03 | — | QED Therapeutics, Inc |
Vosoritide | peptides | EMA | 2024-12-13 | — | BioMarin International Limited |
vosoritide | peptides | FDA | 2023-08-01 | — | BioMarin Pharmaceutical Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.